Cargando…

Diabetic Kidney Disease: A Determinant of Cardiovascular Risk in Type 1 Diabetes

Detalles Bibliográficos
Autores principales:	de Boer, Ian H., Bakris, George L.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	American Diabetes Association 2018
Materias:	Commentaries
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6463621/ https://www.ncbi.nlm.nih.gov/pubmed/29559452 http://dx.doi.org/10.2337/dci17-0053

Ejemplares similares

Slowing the Progression of Diabetic Kidney Disease
por: Blazek, Olivia, et al.
Publicado: (2023)

Finerenone and Cardiovascular Outcomes in Patients With Chronic Kidney Disease and Type 2 Diabetes
por: Filippatos, Gerasimos, et al.
Publicado: (2020)

Modifiability of Composite Cardiovascular Risk Associated With Chronic Kidney Disease in Type 2 Diabetes With Finerenone
por: Agarwal, Rajiv, et al.
Publicado: (2023)

Modifying chronic kidney disease progression with the mineralocorticoid receptor antagonist finerenone in patients with type 2 diabetes
por: DeFronzo, Ralph A., et al.
Publicado: (2022)

Diabetes Management in Chronic Kidney Disease: A Consensus Report by the American Diabetes Association (ADA) and Kidney Disease: Improving Global Outcomes (KDIGO)
por: de Boer, Ian H., et al.
Publicado: (2022)

Hypertension Management in Diabetic Kidney Disease
por: Patney, Vikram, et al.
Publicado: (2015)

Commentary on risk factors for first and subsequent cardiovascular disease events in type 1 diabetes: The Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications study
por: Lin, Chun‐Hsien, et al.
Publicado: (2020)

Cardiovascular and kidney outcomes with finerenone in patients with type 2 diabetes and chronic kidney disease: the FIDELITY pooled analysis
por: Agarwal, Rajiv, et al.
Publicado: (2021)

Intensive risk factor management and cardiovascular autonomic neuropathy in type 2 diabetes in the Action to Control Cardiovascular Risk in Diabetes trial: A post‐hoc analysis
por: Aso, Yoshimasa
Publicado: (2021)

Preventing major adverse cardiovascular events by SGLT-2 inhibition in patients with type 2 diabetes: the role of kidney
por: Giugliano, Dario, et al.
Publicado: (2020)

The importance of improving health literacy to lower cardiovascular risk in type 2 diabetes
por: Hansen, Dominique, et al.
Publicado: (2019)

Unrecognised cardiovascular disease in type 2 diabetes: is it time to act earlier?
por: Schernthaner, Guntram, et al.
Publicado: (2018)

Finerenone efficacy in patients with chronic kidney disease, type 2 diabetes and atherosclerotic cardiovascular disease
por: Filippatos, Gerasimos, et al.
Publicado: (2022)

Tackling Cardiovascular Risk in Type 2 Diabetes: Does Baseline Glucose Control Matter?
por: Nicholls, Stephen J., et al.
Publicado: (2018)

Progression of diabetic kidney disease: Who is at risk?
por: Jamale, T
Publicado: (2020)

Glucagon-like peptide-1 receptor agonists in diabetic kidney disease: A review of their kidney and heart protection
por: Michos, Erin D., et al.
Publicado: (2023)

Dual therapy and diabetic kidney disease
por: Desai, T.
Publicado: (2015)

Impact of empagliflozin on diabetic kidney disease
por: Koya, Daisuke
Publicado: (2017)

Diabetic Kidney Disease: The “Silent” Majority?
por: Yau, Amy, et al.
Publicado: (2021)

Beyond the Glomerulus—Kidney Tubule Markers and Diabetic Kidney Disease Progression
por: Bullen, Alexander L., et al.
Publicado: (2021)

Novel anti-inflammatory drugs for the treatment of diabetic kidney disease
por: Heerspink, Hiddo J. L., et al.
Publicado: (2016)

Treatment of type 2 diabetes in chronic kidney disease: a case for linagliptin in the treatment of diabetes in severe renal impairment
por: Scott, David
Publicado: (2013)

Optimal Early Diagnosis and Monitoring of Diabetic Kidney Disease in Type 2 Diabetes Mellitus: Addressing the Barriers to Albuminuria Testing
por: Christofides, Elena A., et al.
Publicado: (2021)

Aspirin for primary prevention of cardiovascular disease in diabetes
por: Xing, Ying, et al.
Publicado: (2019)

Living with Chronic Kidney Disease and Type 2 Diabetes Mellitus: The Patient and Clinician Perspective
por: Nicholas, Susanne B., et al.
Publicado: (2022)

Management and prevention of cardiovascular disease for type 2 diabetes: Integrating the diabetes management recommendations of AACE, ADA, EASD, AHA, ACC, and ESC()
por: Bloomgarden, Zachary, et al.
Publicado: (2020)

Paradigm Shift or Shifting Paradigm for Type 1 Diabetes
por: Nakayama, Maki, et al.
Publicado: (2012)

ON NO—The Continuing Story of Nitric Oxide, Diabetes, and Cardiovascular Disease
por: Bøtker, Hans Erik, et al.
Publicado: (2013)

Differences in glycemic control between the treatment arms in cardiovascular outcome trials of type 2 diabetes medications do not explain cardiovascular benefits
por: McGuire, Darren K., et al.
Publicado: (2021)

Risk‐benefit analysis of use of statins for primary prevention of cardiovascular disease in subjects without diabetes
por: Chan, Juliana CN
Publicado: (2013)

Commentary on Intraglumerular dysfunction predicts kidney failure in the type 2 diabetes
por: Wada, Jun
Publicado: (2021)

Inflammation Leads the Way on the ROADMAP to Diabetic Kidney Disease
por: Persson, Frederik, et al.
Publicado: (2019)

Prediction of Type 1 Diabetes
por: Erlich, Henry A., et al.
Publicado: (2013)

Cardiovascular benefit in the limelight: shifting type 2 diabetes treatment paradigm towards early combination therapy in patients with overt cardiovascular disease
por: Shehadeh, Naim, et al.
Publicado: (2018)

Microalbuminuria and diabetic retinopathy in type 2 diabetic patients: From risk association to risk prediction
por: Chang, Chia‐Hsuin, et al.
Publicado: (2013)

Mortality Risk in Long-Standing Type 1 Diabetes: Hope and Concern
por: Hamman, Richard F.
Publicado: (2010)

Urinary adiponectin and progression of diabetic nephropathy in type 1 diabetes
por: Ha, Kyoung Hwa, et al.
Publicado: (2015)

History of gestational diabetes and future cardiovascular disease: What have we learned?
por: Hsu, Cherng‐Lan, et al.
Publicado: (2018)

Lessons from a cardiovascular outcome trial with liraglutide in type 2 diabetes
por: Kim, Hae Jin, et al.
Publicado: (2017)

The residual cardiorenal risk in type 2 diabetes
por: Giugliano, Dario, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_m461s60kdgoh0ec0kkvae1ttnm